Research programme: p38 MAP kinase inhibitors - Ambit Biosciences

Drug Profile

Research programme: p38 MAP kinase inhibitors - Ambit Biosciences

Alternative Names: p38 MAP kinase inhibitors research programme - Ambit Biosciences; p38-alpha mitogen-activated protein kinase inhibitors - Ambit Biosciences

Latest Information Update: 20 Apr 2006

Price : $50

At a glance

  • Originator Ambit Biosciences Corporation
  • Class
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 20 Apr 2006 No development reported - Preclinical for Inflammation in USA (unspecified route)
  • 24 Feb 2004 Preclinical trials in Inflammation in USA (unspecified route)
  • 24 Feb 2004 Ambit Biosciences' p38 MAP kinase inhibitors programme is available for partnering (http://www.ambitbio.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top